Pancreatic Neuroendocrine Neoplasms Larger than 4 cm: A Retrospective Observational Study of Surgery, Histology, and Outcome.

neuroendocrine neoplasm pancreas pancreatic surgery tumor size

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
25 Feb 2023
Historique:
received: 02 02 2023
revised: 20 02 2023
accepted: 23 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 12 3 2023
Statut: epublish

Résumé

Pancreatic neuroendocrine neoplasms (pNENs) are often detected as large primary lesions, even with distant metastases, and their prognosis may be difficult to predict. In this retrospective study, we retrieved data of patients treated for a large pNEN in our Surgical Unit (1979-2017) to evaluate the possible prognostic role of clinic-pathological features and surgery. Cox-proportional hazard regression models were used to find possible associations among some variables (clinical features, surgery, and histology) and survival at univariate and multivariate analyses. Among 333 pNENs, we identified 64 patients (19%) with a lesion > 4 cm. Patients' median age was 61 years, median tumor size was 6.0 cm, and 35 (55%) patients had distant metastases at diagnosis. There were 50 (78%) nonfunctioning pNENs, and 31 tumors localized in the body/tail region of the pancreas. Overall, 36 patients underwent a standard pancreatic resection (with 13 associated liver resection/ablation). Regarding histology, 67% of pNENs were N1, and 34% were grade 2. After a median follow-up of 48 months (up to 33 years), 42 patients died of disease. Median survival after surgery was 79 months, and six patients experienced recurrence (median DFS 94 months). At multivariate analysis, distant metastases were associated with a worse outcome, while having undergone radical tumor resection was a protective factor. In our experience, about 20% of pNENs have a size > 4 cm, 78% are nonfunctioning, and 55% show distant metastases at diagnosis. Nevertheless, a long-term survival of more than five years may be achieved after surgery.

Sections du résumé

BACKGROUND BACKGROUND
Pancreatic neuroendocrine neoplasms (pNENs) are often detected as large primary lesions, even with distant metastases, and their prognosis may be difficult to predict.
METHODS METHODS
In this retrospective study, we retrieved data of patients treated for a large pNEN in our Surgical Unit (1979-2017) to evaluate the possible prognostic role of clinic-pathological features and surgery. Cox-proportional hazard regression models were used to find possible associations among some variables (clinical features, surgery, and histology) and survival at univariate and multivariate analyses.
RESULTS RESULTS
Among 333 pNENs, we identified 64 patients (19%) with a lesion > 4 cm. Patients' median age was 61 years, median tumor size was 6.0 cm, and 35 (55%) patients had distant metastases at diagnosis. There were 50 (78%) nonfunctioning pNENs, and 31 tumors localized in the body/tail region of the pancreas. Overall, 36 patients underwent a standard pancreatic resection (with 13 associated liver resection/ablation). Regarding histology, 67% of pNENs were N1, and 34% were grade 2. After a median follow-up of 48 months (up to 33 years), 42 patients died of disease. Median survival after surgery was 79 months, and six patients experienced recurrence (median DFS 94 months). At multivariate analysis, distant metastases were associated with a worse outcome, while having undergone radical tumor resection was a protective factor.
CONCLUSIONS CONCLUSIONS
In our experience, about 20% of pNENs have a size > 4 cm, 78% are nonfunctioning, and 55% show distant metastases at diagnosis. Nevertheless, a long-term survival of more than five years may be achieved after surgery.

Identifiants

pubmed: 36902627
pii: jcm12051840
doi: 10.3390/jcm12051840
pmc: PMC10003654
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biomedicines. 2022 May 02;10(5):
pubmed: 35625790
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Dig Surg. 2005;22(3):157-62
pubmed: 16043962
Ann Surg. 2019 Sep;270(3):422-433
pubmed: 31283562
Am J Surg. 2014 Nov;208(5):775-780
pubmed: 24997491
Surgery. 2012 Jul;152(1):107-13
pubmed: 22503317
HPB (Oxford). 2018 Mar;20(3):251-259
pubmed: 28988702
Am Surg. 2020 May;86(5):458-466
pubmed: 32684030
Br J Surg. 2009 Feb;96(2):175-84
pubmed: 19160361
Ann Surg Oncol. 2015 Mar;22(3):1000-7
pubmed: 25190116
Langenbecks Arch Surg. 2015 Aug;400(6):715-23
pubmed: 26198970
Surgery. 2015 Dec;158(6):1556-63
pubmed: 26070847
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Ann Surg Oncol. 2018 Aug;25(8):2467-2474
pubmed: 29789972
Ann Oncol. 2005 Nov;16(11):1806-10
pubmed: 16085691
ANZ J Surg. 2011 Jan;81(1-2):79-85
pubmed: 21299804
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Surgery. 2013 Oct;154(4):785-91; discussion 791-3
pubmed: 24074416
J Am Coll Surg. 2007 Oct;205(4):558-63
pubmed: 17903729
Scand J Gastroenterol. 2016;51(2):245-52
pubmed: 26513346
Ann Surg Oncol. 2018 Mar;25(3):647-654
pubmed: 29235006
Pancreatology. 2017 May - Jun;17(3):471-477
pubmed: 28320587
Dig Liver Dis. 2019 May;51(5):735-740
pubmed: 30723019
Surgery. 2011 Jul;150(1):75-82
pubmed: 21683859
Nat Rev Clin Oncol. 2009 Jul;6(7):419-28
pubmed: 19506584
J Gastrointest Surg. 2019 Jul;23(7):1392-1400
pubmed: 30353489
Arch Surg. 2011 May;146(5):534-8
pubmed: 21576607
Ann Oncol. 2008 Oct;19(10):1727-33
pubmed: 18515795
J Gastrointest Surg. 2010 Mar;14(3):541-8
pubmed: 19997980
J Am Coll Surg. 2003 Jul;197(1):29-37
pubmed: 12831921
Endocr Relat Cancer. 2005 Dec;12(4):1083-92
pubmed: 16322345
Virchows Arch. 2006 Oct;449(4):395-401
pubmed: 16967267
Sci Rep. 2018 May 8;8(1):7271
pubmed: 29739948
Gastroenterology. 2008 Nov;135(5):1469-92
pubmed: 18703061
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Ann Surg. 2008 Mar;247(3):490-500
pubmed: 18376195
Hum Pathol. 2009 Jan;40(1):30-40
pubmed: 18715612
Eur J Surg Oncol. 2019 May;45(5):755-760
pubmed: 30366875
Ann Surg. 2007 Feb;245(2):273-81
pubmed: 17245182
Mod Pathol. 2010 Jun;23(6):824-33
pubmed: 20305616
Ann Surg. 2005 May;241(5):776-83; discussion 783-5
pubmed: 15849513
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Gastrointest Surg. 2011 Jan;15(1):175-83
pubmed: 21103949
Pancreas. 2020 Mar;49(3):381-386
pubmed: 32132507

Auteurs

Anna Caterina Milanetto (AC)

Pancreatic and Endocrine Digestive Surgical Group, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy.

Anna-Lea Gais Zürcher (AL)

Pancreatic and Endocrine Digestive Surgical Group, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy.

Alina David (A)

Pancreatic and Endocrine Digestive Surgical Group, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy.

Matteo Fassan (M)

Surgical Pathology Unit, Department of Medicine, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy.

Claudio Pasquali (C)

Pancreatic and Endocrine Digestive Surgical Group, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy.

Classifications MeSH